Published in Cancer Weekly, November 13th, 2001
Ubiquitin ligases are involved in cell division and the progression of certain cancers. Research on this target class is an important new area in the field of oncology. Rigel focuses on the study ubiquitin ligases and their applications in oncologic, inflammatory and viral diseases.
Under the terms of the agreement, Evotec OAI will use its integrated drug...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.